Cairo – Mubahser: October Pharma said it expects to incur losses of EGP 50 million in 2017, amid the continuous increase in the production cost.
The drug firm studies suspending the production of 30 medicines due to the sharp devaluation of the Egyptian against the US dollar.
October Pharma reported net profits of EGP 24.4 million for the first nine months of 2016.
